研究纳入 124 例新诊断的 ELN 2017 中高危 AML 患者，结果显示，该方案的完全缓解（CR）率和微小残留病（MRD）阴性率分别为 79% 和 64%，1 年和 2 年总生存率分别为 61% 和 48%，且治疗相关死亡率低，表明 V - FLAI 可使中高危 AML 患者获得持久的生存获益，是一种有潜力 ...

Early clearance of measurable residual disease (MRD) after induction therapy in patients with acute myeloid leukemia (AML) is associated with significantly better relapse-free survival (RFS ...

为优化 AML 患者异基因造血干细胞移植（Allo-HCT ... 此外，研究还发现年龄大于 55 岁和移植前微小残留病（MRD）阳性的患者，OS 和 LFS 较低。而使用基于移植后环磷酰胺（PTCY）的预防方案与改善的 LFS 相关（HR：0.67，95% CI：0.5-0.91，p=0.01） 。 在研究结论与讨论 ...

Today, OGT announces the North American launch of its new next-generation sequencing (NGS) SureSeq ™ Myeloid MRD Panel, which provides a flexible NGS workflow for the detection of ultra-low ...

Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt ...

Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment ...

Break Through Cancer: A Phase 2 trial studying whether the combination of revumenib and venetoclax can eliminate MRD in patients with AML and extend progression-free survival. The trial is being ...

Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint ... through the frontline AML combination setting – – Management to ...

Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical ...